Interaction between the 5-HT system and the basal ganglia: functional implication and therapeutic perspective in Parkinson's disease
- PMID: 24672433
- PMCID: PMC3955837
- DOI: 10.3389/fncir.2014.00021
Interaction between the 5-HT system and the basal ganglia: functional implication and therapeutic perspective in Parkinson's disease
Abstract
The neurotransmitter serotonin (5-HT) has a multifaceted function in the modulation of information processing through the activation of multiple receptor families, including G-protein-coupled receptor subtypes (5-HT1, 5-HT2, 5-HT4-7) and ligand-gated ion channels (5-HT3). The largest population of serotonergic neurons is located in the midbrain, specifically in the raphe nuclei. Although the medial and dorsal raphe nucleus (DRN) share common projecting areas, in the basal ganglia (BG) nuclei serotonergic innervations come mainly from the DRN. The BG are a highly organized network of subcortical nuclei composed of the striatum (caudate and putamen), subthalamic nucleus (STN), internal and external globus pallidus (or entopeduncular nucleus in rodents, GPi/EP and GPe) and substantia nigra (pars compacta, SNc, and pars reticulata, SNr). The BG are part of the cortico-BG-thalamic circuits, which play a role in many functions like motor control, emotion, and cognition and are critically involved in diseases such as Parkinson's disease (PD). This review provides an overview of serotonergic modulation of the BG at the functional level and a discussion of how this interaction may be relevant to treating PD and the motor complications induced by chronic treatment with L-DOPA.
Keywords: 5-HT; L-DOPA induced dyskinesia; Parkinson's disease; basal ganglia; electrophysiology.
Figures
Similar articles
-
Functional organization of the basal ganglia: therapeutic implications for Parkinson's disease.Mov Disord. 2008;23 Suppl 3:S548-59. doi: 10.1002/mds.22062. Mov Disord. 2008. PMID: 18781672 Review.
-
Serotonin modulation of the basal ganglia circuitry: therapeutic implication for Parkinson's disease and other motor disorders.Prog Brain Res. 2008;172:423-63. doi: 10.1016/S0079-6123(08)00921-7. Prog Brain Res. 2008. PMID: 18772045 Review.
-
Serotonin-dependent depression in Parkinson's disease: a role for the subthalamic nucleus?Neuropharmacology. 2011 Sep;61(3):387-99. doi: 10.1016/j.neuropharm.2011.01.006. Epub 2011 Jan 18. Neuropharmacology. 2011. PMID: 21251918 Review.
-
Basal ganglia serotonin 1B receptors in parkinsonian monkeys with L-DOPA-induced dyskinesia.Biochem Pharmacol. 2013 Oct 1;86(7):970-8. doi: 10.1016/j.bcp.2013.08.005. Epub 2013 Aug 14. Biochem Pharmacol. 2013. PMID: 23954709
-
Lack of depotentiation at basal ganglia output neurons in PD patients with levodopa-induced dyskinesia.Neurobiol Dis. 2014 Nov;71:24-33. doi: 10.1016/j.nbd.2014.08.002. Epub 2014 Aug 10. Neurobiol Dis. 2014. PMID: 25116960
Cited by
-
Associated factors and abnormal dorsal raphe nucleus connectivity patterns of freezing of gait in Parkinson's disease.J Neurol. 2022 Dec;269(12):6452-6466. doi: 10.1007/s00415-022-11294-6. Epub 2022 Aug 6. J Neurol. 2022. PMID: 35933494
-
Contributions of Basal Ganglia Circuits to Perception, Attention, and Consciousness.J Cogn Neurosci. 2024 Jul 1;36(8):1620-1642. doi: 10.1162/jocn_a_02177. J Cogn Neurosci. 2024. PMID: 38695762 Free PMC article. Review.
-
Chronic 3,4-Methylenedioxymethamphetamine (MDMA) Use Is Related to Glutamate and GABA Concentrations in the Striatum But Not the Anterior Cingulate Cortex.Int J Neuropsychopharmacol. 2023 Jun 23;26(6):438-450. doi: 10.1093/ijnp/pyad023. Int J Neuropsychopharmacol. 2023. PMID: 37235749 Free PMC article.
-
What Gene Mutations Affect Serotonin in Mice?ACS Chem Neurosci. 2017 May 17;8(5):987-995. doi: 10.1021/acschemneuro.6b00441. Epub 2017 Apr 27. ACS Chem Neurosci. 2017. PMID: 28418237 Free PMC article.
-
A New Synuclein-Transgenic Mouse Model for Early Parkinson's Reveals Molecular Features of Preclinical Disease.Mol Neurobiol. 2021 Feb;58(2):576-602. doi: 10.1007/s12035-020-02085-z. Epub 2020 Sep 30. Mol Neurobiol. 2021. PMID: 32997293 Free PMC article.
References
-
- Aguiar L. M., Macedo D. S., Vasconcelos S. M., Oliveira A. A., De Sousa F. C., Viana G. S. (2008). CSC, an adenosine A(2A) receptor antagonist and MAO B inhibitor, reverses behavior, monoamine neurotransmission, and amino acid alterations in the 6-OHDA-lesioned rats. Brain Res. 1191, 192–199 10.1016/j.brainres.2007.11.051 - DOI - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous
